MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · Real-Time Price · USD

36.35

-2.72 (-6.96%)

At close: Apr 1, 2025, 4:00 PM

37.75

+1.40 (3.84%)

After-hours: Apr 1, 2025, 4:53 PM EDT

MLTX Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	30.32	22.32	23.01	21.66
Research & Development	112.77	31.8	42.05	12.64
Operating Expenses	143.09	54.12	65.06	34.29
Operating Income	-143.09	-54.12	-65.06	-34.29
Currency Exchange Gain (Loss)	0.04	0.15	0.33	-0.07
Other Non Operating Income (Expenses)	22.09	9.99	0.27	-0
EBT Excluding Unusual Items	-120.96	-43.98	-64.47	-34.37
Other Unusual Items	-	-	-	-30
Pretax Income	-120.96	-43.98	-64.47	-64.37
Income Tax Expense	0.28	0.09	0.04	0.01
Earnings From Continuing Operations	-121.24	-44.08	-64.51	-64.37
Minority Interest in Earnings	2.31	8.07	14.53	-
Net Income	-118.94	-36.01	-49.97	-64.37
Net Income to Common	-118.94	-36.01	-49.97	-64.37
Shares Outstanding (Basic)	63	49	29	8
Shares Outstanding (Diluted)	63	49	29	8
Shares Change (YoY)	27.99%	67.30%	274.47%	-
EPS (Basic)	-1.89	-0.73	-1.70	-8.21
EPS (Diluted)	-1.89	-0.73	-1.70	-8.21
Free Cash Flow	-117.11	-43.06	-55.91	-42.27
Free Cash Flow Per Share	-1.86	-0.88	-1.90	-5.39
EBITDA	-141.71	-53.75	-64.9	-34.29
D&A For EBITDA	1.38	0.37	0.16	0.01
EBIT	-143.09	-54.12	-65.06	-34.29

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q